Providing pre-exposure prophylaxis (PrEP) treatment to men who have sex with men at high risk of contracting HIV in England would be cost-effective and could prevent 25 percent of cases of infection, according to UCL research.
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
Allergy Therapeutics has begun dosing in a mid-stage trial designed to assess the dose-response and safety of its ultra-short course PQ Grass immunotherapy, which targets the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.
Gilead’s Yescarta - recently acquired through its purchase of Kite Pharma - has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
More than one third of patients referred by GPs to Weight Watchers in a bid to stave off diabetes saw their blood sugar levels return to normal, a study published in the British Medical Journal has found.
A ‘no-deal’ Brexit that ends healthcare arrangements between the UK and the EU could end up costing the NHS as much as £500 million a year, warns a new paper published by the Brexit Healthcare Alliance, on the back of an analysis by the Nuffield Trust.